/
Arbutus Biopharma Corporation ( Arbutus , the Company , we , us , and our ) is a clinical-stage biopharmaceutical company focused on infectious disease. We are currently developing imdusiran (AB-729), our proprietary, GalNAc-conjugated, subcutaneously-delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, our proprietary oral PD-L1 inhibitor, for the treatment of chron…
$4.25
$0.18 (-4.06%)
Price from 41 days ago
The business is unprofitable at the operating level (-270.96% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 128.2% YoY with margins expanding 965.8pp.
Negative free cash flow of -$40M. The business is consuming cash, not generating it.
5.1x earnings. The multiple is below average. Either the market is pricing in deterioration you should investigate, or there's genuine value here.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$191M
▲ +128.2% YoY
Net Income (TTM)
$161M
▲ +52.1% YoY
Op. Margin
81.72%
▲ +965.8pp YoY
ROIC
98.77%
▲ +24.1pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$34M
▲ +39.1% YoY
Op. Cash Flow (TTM)
-$34M
▲ +38.9% YoY
Net Debt
-$95M
Net Cash Position
Cash & Equiv.
$95M
5Y CAGR: +15.3%
Continue Research